A Phase 2 interventional study of PRO 140 and PRO 140 in HIV Infections, sponsored by CytoDyn, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-07-15.
Sponsored by CytoDyn, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,802 studies in HIV Infections with a site in United States — 83 open to participants now, 140 under way, 11 of them phase 3. HIV Infections · United States.
Among the 2,802 studies in HIV Infections with a site in United States, this one is the 1,565th largest by enrollment of the 2,150 interventional ones that give a count, is one of 105 that started in 2007, is one of 478 in phase 2, and was the 1,818th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →83 of the 2,802 studies in HIV Infections with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
Louisiana State University Health Sciences Center in New Orleans · Sites in United States
Ages 40+
American University · Sites in United States
Ages 18+ · Men only
Gilead Sciences · Sites in United States, Australia, Japan
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,802 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 749 · Phase 2 588 · Phase 3 337 · Phase 4 157
First in 1984; this study’s year is marked. 105 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 60 across the 2,150 interventional studies, 135 across the 350 observational. Of the 2,530 that completed or were terminated, 558 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
857 of 2,802 have an industry lead sponsor. The 10 most frequent:
CytoDyn, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.
CytoDyn, Inc. has 4 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
51 of the studies in HIV Infections with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06550804Phase 3University of Illinois at ChicagoTesting a Real-time Electronic Antiretroviral Adherence Monitoring Intervention | 2027-03 |
| NCT04833829Emory UniversityCross-disciplinary HIV Integrated Mental Health Support Intervention | 2026-11 |
| NCT04577313University of ConnecticutHIV Treatment Adherence Dose Determination Trial | 2026-11-30 |
| NCT06679751Boston Medical CenterInfectious Disease (ID) Testing OUtreach in Carceral Hubs | 2026-12 |
| NCT06868641Columbia UniversityThe TAIL-PrEP Study | 2026-12 |
Add all 51 to your calendar (.ics) → With an account.
Among the 2,802 studies in HIV Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 mg/kg PRO 140, one IV dose (N=10)
Drug: PRO 140
5 mg/kg PRO 140, one IV dose (N=10)
Drug: PRO 140
Placebo, one IV dose (N=10)
Drug: Placebo
Maximum Change in Viral Load Following Initiation of Treatment.
The primary end point was the maximum change from baseline in viral load following initiation of treatment, defined as HIV-1 copies/mL, measured by the Roche Amplicor HIV-1 Monitor UltraSensitive™ Test (lower limit of detection \[LLD\] = 48 copies/mL).
Time frame: 59 days
Recruitment was from December 2007 to August 2008
| Milestone | Arm 1 | Arm 2 | Arm 3 |
|---|---|---|---|
| Started | 10 | 10 | 11 |
| Completed | 10 | 10 | 11 |
| Not completed | 0 | 0 | 0 |
The primary end point was the maximum change from baseline in viral load following initiation of treatment, defined as HIV-1 copies/mL, measured by the Roche Amplicor HIV-1 Monitor UltraSensitive™ Test (lower limit of detection \[LLD\] = 48 copies/mL).
| Log10copies HIV-1 RNA/mL | Arm 1 | Arm 2 | Arm 3 |
|---|---|---|---|
| Maximum Change in Viral Load Following Initiation of Treatment. | -1.67 ± 0.639 | -1.83 ± 0.229 | -0.32 ± 0.244 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1 | — | 0/10 (0%) | 8/10 (80%) |
| Arm 2 | — | 0/10 (0%) | 7/10 (70%) |
| Arm 3 | — | 0/11 (0%) | 11/11 (100%) |
| Event | Arm 1 | Arm 2 | Arm 3 |
|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 0/10 | 0/10 | 3/11 |
| Upper respiratory tract infectionInfections and infestations | 0/10 | 2/10 | 1/11 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/10 | 0/10 | 0/11 |
| HeadacheNervous system disorders | 2/10 | 1/10 | 0/11 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 0/10 | 2/10 | 0/11 |
| DiarrhoeaGastrointestinal disorders | 0/10 | 1/10 | 2/11 |
| SunburnInjury, poisoning and procedural complications | 0/10 | 0/10 | 2/11 |
| Neutrophil count decreasedInvestigations | 0/10 | 0/10 | 2/11 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 1/10 | 0/10 | 2/11 |
| LymphadenopathyBlood and lymphatic system disorders | 1/10 | 0/10 | 1/11 |
| Age, Categorical(Participants) | Arm 1 | Arm 2 | Arm 3 | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 10 | 11 | 31 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Arm 1 | Arm 2 | Arm 3 | Total |
|---|---|---|---|---|
| Mean | 42.5 ± 10.17 | 42 ± 9.88 | 38 ± 11.65 | 40.7 ± 10.48 |
| Sex: Female, Male(Participants) | Arm 1 | Arm 2 | Arm 3 | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 10 | 10 | 11 | 31 |
| Region of Enrollment(participants) | Arm 1 | Arm 2 | Arm 3 | Total |
|---|---|---|---|---|
| United States | 10 | 10 | 11 | 31 |
The record gives a start of Dec 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2013, 4 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leronlimab